Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Commits To Dual Branded And Generic Model

CEO Maintains ‘World Class’ Generics Business And Innovative Interests Are Complementary

Executive Summary

Teva’s innovative and generic interests can not only co-exist but are complementary, CEO Richard Francis has set out, in response to questions over whether the Israeli giant would consider splitting its businesses to focus more on branded drugs.

You may also be interested in...



Stick, Twist Or Split? Generics Industry’s Big Three Place Their Bets

With Teva and Viatris recently under new management and Sandoz having last year split from former parent company Novartis, the three off-patent industry leaders are adopting different strategies for how they balance their generics and biosimilars interests with more innovative ventures.

For Sale, Buyer Sought: Teva Confirms API Unit Is On The Block

Teva had told investors last year that it believed it was stymying its API unit’s growth by not allowing it to stand taller on its own two feet. Now the Israeli firm has confirmed that the business, TAPI, is up for sale.

Teva Responds To API Unit Selloff Rumors

Amid rumors that Teva is mulling a potential sale of its APIs business, TAPI, the Israeli firm has underlined the strength of the unit while acknowledging that it continuously reviews such opportunities.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153303

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel